NCT06052436View on ClinicalTrials.gov

Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Systemic Inflammatory Response Syndrome
Interventions
BIOLOGICAL

Allogeneic thyTreg 5.000.000

Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)

BIOLOGICAL

Allogeneic thyTreg 10.000.000

Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)

Trial Locations (1)

28007

RECRUITING

Hospital General Universitario Gregorio Marañon, Madrid

All Listed Sponsors
collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Hospital General Universitario Gregorio Marañon

OTHER